ClinicalTrials.gg
TerminatedNCT04753385UNCOVERUpdated Dec 20, 2024

The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

An observational study in Treatment Resistant Depression, sponsored by LivaNova. Terminated at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by LivaNova · Observational

Why this study was terminated
UNCOVER terminated early based on low enrollment and lack of device data collected making analysis unfeasible.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
138
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects participating in the RECOVER clinical trial (A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression).

Read the detailed description

A prospective, observational, exploratory study collecting passive and active behavioral, environmental and physiological data, via the use of an Android smartphone application and Study Watch.

This sub-study is only open to sites participating in the RECOVER clinical study.

All subjects participating in the RECOVER clinical trial at active UNCOVER sites will be offered participation in this sub-study.

Subjects who opt-in to the Mood App portion of the sub-study will be followed for a minimum of 12 months and a maximum of 60 months for the Mood App portion of the sub-study.

Subjects who opt-in to the use of the Study Watch portion of the sub-study will be followed for a minimum of 12 months and maximum of 24 months for the Study Watch portion of the sub-study.

02

Conditions studied

  • Treatment Resistant Depression

Keywords

  • Depression
  • TRD
03

In context

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

This study's enrollment of 138 is above the median of 80 across 49 observational studies indexed under Depressive Disorder, Treatment-Resistant.

Browse Depressive Disorder, Treatment-Resistant studies →

Lead sponsor

LivaNova is the lead sponsor of 40 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This sub-study is only open to sites participating in the RECOVER clinical study.

All subjects participating in the RECOVER clinical trial at active UNCOVER sites will be offered participation in this sub-study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects

  1. Current consented subject in the RECOVER clinical trial;
  2. Adult (i.e. ≥ 18 years of age, unless a resident of any U.S. state where the age of majority is 19, in which case must be ≥ 19 years of age);
  3. Able and willing to provide written for this sub-study;
  4. Able and willing to comply with all study procedures;
  5. Able to read and speak English.

Phone Application

  1. Have a personal Google user account or be willing to create and own a personal Google user account;
  2. Owns a personal Android smartphone with a data plan and is the sole user of that smartphone;
  3. Agrees to download and maintain the phone application onto personal Android smartphone for the duration of the sub-study;

Study Watch

  1. Willing to comply with Study Watch wearing and recharging requirements

Exclusion criteria

Exclusion Criteria:

All Subjects

  1. Any condition or situation the Principal Investigator determines as inappropriate for study inclusion

Phone Application

No additional exclusion criteria for phone application

Study Watch

  1. Subjects with known severe allergy to nickel or metal jewelry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
138 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Percentage of PHQ-8 tasks

    Percentage of PHQ-8 tasks completed over the duration of the study

    Time frame: Through study completion; Average 2 years

  2. Percentage of Voice Diary tasks

    Percentage of Voice Diary tasks completed over the duration of the study

    Time frame: Through study completion; Average 2 years

  3. Number of ping sensor recordings

    Number of ping sensor recordings over the duration of the study

    Time frame: Through study completion; Average 2 years

  4. Number of hours of watch wear time

    Number of hours of watch wear time over the duration of the study

    Time frame: Through study completion; Average 2 years

07

Study locations

33 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • SF-Care, Inc.
    San Rafael, California 94901, United States
  • Kind Research Group
    Boca Raton, Florida 33431, United States
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • Nova Psychiatry Inc.
    Orlando, Florida 32803, United States
  • Advanced Mental Health Care Inc.
    Royal Palm Beach, Florida 33411, United States
  • Florida Center for TMS
    Saint Augustine, Florida 94901, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • AMR-Baber Research, Inc.
    Naperville, Illinois 60563, United States
  • Psychiatric Medicine Associates, LLC
    Skokie, Illinois 60076, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62794, United States
  • Beacon Medical Group Behavioral Health
    South Bend, Indiana 46601, United States
  • Sheppard Pratt Health Systems
    Baltimore, Maryland 21204, United States
  • Michigan Clinical Research Institute PC
    Ann Arbor, Michigan 48105, United States
  • Psychiatric Care and Research
    O'Fallon, Missouri 633668, United States
  • PsychCare Consultants Research
    Saint Louis, Missouri 63128, United States
  • Alivation Research, LLC
    Lincoln, Nebraska 68526, United States
  • Hapworth Research Inc.
    New York, New York 10019, United States
  • Center for Neuropsychiatry and Brain Stimulation (CNBS)
    Cary, North Carolina 27519, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • OU-SOCM Dept of Psychiatry
    Tulsa, Oklahoma 74135, United States
  • Scranton Medical Institutes
    Moosic, Pennsylvania 18507, United States
  • University of Pennsylvania Perelman School of Medicine
    Philadelphia, Pennsylvania 19104-4283, United States
  • UT Health Austin
    Austin, Texas 78712, United States
  • UT Center of Excellence on Mood Disorders
    Houston, Texas 77054, United States
  • North Pointe Psychiatry
    Lewisville, Texas 75057, United States
  • Neuropsychiatric Associates, Plc
    Woodstock, Vermont 05091, United States
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
  • Seattle Neuropsychiatric Treatment Center
    Bellevue, Washington 98004, United States
  • Center for Anxiety and Depression
    Mercer Island, Washington 98040, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04753385
Lead sponsor
LivaNova
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Mar 23, 2021
Primary completion
Sep 6, 2024
Completion
Sep 6, 2024
Last update
Dec 20, 2024

Study contacts

Charles Conway, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion